Innovative Electrochemical Sensing Devices for Real-time Carboplatin Monitoring in Drug Delivery Nanosystems

Schneider Hasseyid^*
*Correspondence: Schneider Hasseyid, Department of Biopharmaceutics, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates, Email:

Introduction

Carboplatin, a second-generation platinum-based chemotherapy drug, plays a crucial role in treating various cancers, including ovarian, lung and head and neck cancers. Despite its efficacy, the optimal therapeutic use of carboplatin is challenged by its narrow therapeutic window and the potential for severe side effects. The development of advanced drug delivery nanosystems (DDNs) has significantly improved the precision of carboplatin administration. However, to maximize therapeutic benefits and minimize adverse effects, realtime monitoring of drug levels within these nanosystems is essential. Recent innovations in electrochemical sensing devices have paved the way for more effective and real-time monitoring of carboplatin. This article explores these cutting-edge technologies and their potential impact on cancer therapy [1].

Electrochemical sensing has emerged as a powerful tool for realtime monitoring of drug levels due to its high sensitivity, selectivity and the ability to provide continuous data. Recent advancements in electrode materials have significantly enhanced the performance of electrochemical sensors. Nanomaterials such as carbon nanotubes (CNTs), graphene and Metal-Organic Frameworks (MOFs) offer remarkable electrical conductivity, large surface areas and catalytic properties. These materials are integrated into sensors to improve sensitivity and detection limits for carboplatin. For instance, graphene-based electrodes provide excellent charge transfer rates and are highly effective in detecting low concentrations of carboplatin [2].

Description

To achieve high selectivity for carboplatin, electrodes are functionalized with specific chemical moieties. This process involves attaching molecules that selectively interact with carboplatin, thereby enhancing the sensor's ability to discriminate it from other substances in complex biological environments. Recent approaches include the use of Molecularly Imprinted Polymers (MIPs) and aptamers—short DNA or RNA sequences that bind specifically to carboplatin. These functionalized electrodes can provide accurate and real-time data on drug levels. Integrating electrochemical sensors with Drug Delivery Nanosystems (DDNs) is a groundbreaking advancement. DDNs, such as liposomes, dendrimers and polymeric nanoparticles, are designed to deliver drugs precisely to targeted cells or tissues. By incorporating electrochemical sensors directly into these nanosystems, researchers can continuously monitor carboplatin levels as it is released and distributed within the body. This integration ensures that therapeutic levels are maintained while avoiding toxic concentrations [3].

By providing continuous feedback on drug levels, electrochemical sensors allow for more precise control of carboplatin delivery. This precision helps maintain therapeutic drug levels, improving treatment efficacy and reducing the likelihood of relapse or resistance. Real-time monitoring helps to avoid overdosage and underdosage, thereby minimizing side effects such as nephrotoxicity and myelosuppression. This personalized approach to chemotherapy ensures that patients receive the most effective dose with the least risk of adverse reactions. With better monitoring and control, patients can experience more effective treatment with fewer complications. This translates to improved overall outcomes and quality of life, making cancer therapy more manageable and less burdensome. The field of electrochemical sensing for drug delivery is rapidly evolving. Future research may focus on developing even more sensitive and selective sensors, exploring new materials and functionalization strategies and enhancing integration techniques with nanosystems. Additionally, advancements in data analysis and artificial intelligence could further refine real-time monitoring, providing deeper insights into drug dynamics and patient responses [4].

Innovative electrochemical sensing devices represent a significant leap forward in the real-time monitoring of carboplatin within drug delivery nanosystems. By improving the precision of drug administration and enhancing patient safety, these technologies hold the potential to revolutionize cancer therapy. As research continues to advance, the integration of electrochemical sensors with DDNs will likely become a standard practice, paving the way for more effective and personalized cancer treatments [5].

Conclusion

The integration of innovative electrochemical sensing devices into drug delivery nanosystems represents a transformative development in cancer treatment. By enabling real-time monitoring of carboplatin levels, these advanced sensors offer unparalleled precision in drug administration, significantly enhancing therapeutic efficacy while minimizing the risk of adverse effects. As the technology continues to evolve, it promises to redefine the landscape of chemotherapy, making treatments more effective and personalized. The ongoing advancements in sensor materials, functionalization techniques and nanosystem integration hold the potential to further revolutionize cancer therapy, leading to improved patient outcomes and a better quality of life for those undergoing treatment. As we move forward, the synergy between electrochemical sensing and drug delivery nanosystems will be pivotal in advancing the field of oncology and realizing the full potential of targeted cancer therapies.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Sun, Leming, Hongmei Liu, Yanqi Ye and Yang Lei, et al. "Smart nanoparticles for cancer therapy."Signal Transduct Target. Ther8 (2023): 418.

   Google Scholar, Crossref, Indexed at

2. Aloss, Kenan and Peter Hamar. "Recent preclinical and clinical progress in liposomal doxorubicin."Pharmaceutics15 (2023): 893.

   Google Scholar, Crossref, Indexed at

3. Katsumata, Noriyuki, Makoto Yasuda, Fumiaki Takahashi and Seiji Isonishi, et al. "Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial."Lancet 374 (2009): 1331-1338.

   Google Scholar, Crossref, Indexed at

4. Oun, Rabbab, Yvonne E. Moussa and Nial J. Wheate. "The side effects of platinum-based chemotherapy drugs: A review for chemists."Dalton Trans 47 (2018): 6645-6653.

   Google Scholar, Crossref, Indexed at

5. Alavi, Seyed Ebrahim, Aun Raza, Maedeh Koohi Moftakhari Esfahani and Azim Akbarzadeh, et al. "Carboplatin niosomal nanoplatform for potentiated chemotherapy."J Pharm Sci 111 (2022): 3029-3037.

   Google Scholar, Crossref, Indexed at